We have previously reported on development of non-invasive fPSA-targeted radiotheranostics, including PET-based detection of metastatic disease, assessment of lesion specific AR-activity, and prostate-tumor-specific delivery of both alpha and beta radionuclides [8,9,10]. This evidence concerns the gene AR and neoplasm.